65 completed, 43 active not recruiting, 29 recruiting, 13 unknown. 175 Phase 3, 13 Phase 2.
By phase and status
| Phase | Trials | Status |
|---|
| Phase 3 | 175 | Completed 65, Active not recruiting 43, Recruiting 29, Unknown 13, Not yet recruiting 12, Terminated 9, Withdrawn 4 |
| Phase 2 | 13 | Completed 4, Recruiting 3, Not yet recruiting 2, Unknown 2, Terminated 1, Withdrawn 1 |
Follow Lenalidomide: new trials by email Literature Review of Lenalidomide trials Research Report on Lenalidomide
Trials (filtered) newest first · largest first
All 175 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma Anitocabtagene Autoleucel, Isatuximab, Bortezomib - Newly Diagnosed Multiple Myeloma | Phase 3 | Not yet recruiting | 750 | 2027-02-01 | 2026-11-16 |
A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma Anitocabtagene autoleucel, Daratumumab, Bortezomib - Newly Diagnosed Multiple Myeloma | Phase 3 | Not yet recruiting | 600 | 2027-01-01 | 2026-10-21 |
Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma Daratumumab and Recombinant Human Hyaluronidase, Lenalidomide, Bortezomib - Multiple Myeloma (MM) | Phase 2 / Phase 3 | Not yet recruiting | 920 | 2026-12-23 | 2026-10-22 |
A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible Ramantamig, Daratumumab, Bortezomib - Multiple Myeloma | Phase 3 | Not yet recruiting | 1000 | 2026-12-14 | 2026-11-04 |
A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010) MK-1045, Zilovertamab vedotin, Rituximab - Lymphoma, Large B-Cell, Diffuse, Diffuse Large B-Cell Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | 470 | 2026-12-13 | 2026-11-05 |
Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma Arm A: Belantamab Mafodotin, Arm B: Daratumumab Hyaluronidase, Bortezomib - Multiple Myeloma | Phase 3 | Recruiting | 500 | 2026-12-01 | 2026-11-12 |
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6). AZD0120, Cyclophosphamide, Fludarabine - Newly Diagnosed Multiple Myeloma (NDMM) | Phase 3 | Recruiting | 750 | 2026-09-24 | 2026-10-21 |
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned Ramantamig, Daratumumab, Lenalidomide - Multiple Myeloma | Phase 3 | Recruiting | 1000 | 2026-09-09 | 2026-11-03 |
A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease Teclistamab, Talquetamab, Daratumumab (Subcutaneously) - Multiple Myeloma (MM) | Phase 3 | Not yet recruiting | 248 | 2026-09-01 | 2026-07-31 |
Efficacy and Safety of Lenalidomide in Patients With IgG4-Related Disease Lenalidomide, Placebo - Immunoglobulin G4-Related Disease | Phase 3 | Not yet recruiting | 146 | 2026-08-01 | 2026-07-22 |
A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) TQB3909 Tablets, Bendamustine Injection, Rituximab injection - Small Lymphocytic Lymppho, Relapsed/Refractory Chronic Lymphocytic Leukemia | Phase 3 | Not yet recruiting | 128 | 2026-08-01 | 2026-08-11 |
Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level Daratumumab, Lenalidomide, Dexamethasone - Multiple Myeloma (MM), Plasma Cell Leukemia (PCL) | Phase 3 | Recruiting | 1226 | 2026-07-03 | 2026-11-16 |
A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma Orelabrutinib, obinutuzumab, Lenalidomide - Follicular Lymphoma ( FL) | Phase 3 | Not yet recruiting | 652 | 2026-07-01 | 2026-07-22 |
GMMG-HD11/DSMM XXI/64007957MMY3010 Teclistamab, Daratumumab, Lenalidomide - Multiple Myeloma | Phase 3 | Not yet recruiting | 399 | 2026-06-30 | 2026-06-26 |
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT AZD0120, Daratumumab, Dexamethasone - Newly Diagnosed Multiple Myeloma | Phase 3 | Recruiting | 750 | 2026-06-26 | 2026-08-14 |
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma SCTB35 injection, Rituximab, Lenalidomide - Follicular Lymphoma (FL) | Phase 3 | Recruiting | 93 | 2026-06-09 | 2026-08-13 |
A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) Linvoseltamab, Bortezomib, Lenalidomide - Multiple Myeloma (MM) | Phase 2 / Phase 3 | Withdrawn | | 2026-06-05 | 2026-06-18 |
IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma IMM0306 2.0 mg/kg, Placebo, Lenalidomide 20 mg - Relapsed/Refractory Follicular Lymphoma | Phase 3 | Not yet recruiting | 198 | 2026-02-01 | 2026-01-27 |
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant Etentamig, Lenalidomide, Daratumumab - Multiple Myeloma | Phase 2 / Phase 3 | Recruiting | 680 | 2026-01-08 | 2026-10-19 |
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant SCTC21C, Bortezomib, Lenalidomide - Multiple Myeloma (MM) | Phase 3 | Recruiting | 292 | 2025-12-29 | 2026-01-29 |
Showing 20 of 175. Sign in to see all of them.
Conditions studied
Multiple Myeloma (100) · Lymphoma, Follicular (19) · Lymphoma, Large B-Cell, Diffuse (13) · Recurrence (13) · Neoplasms, Plasma Cell (10) · Lymphoma (7) · Lymphoma, B-Cell, Marginal Zone (6) · Lymphoma, Non-Hodgkin (6) · Anemia (4) · Hematologic Diseases (4) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lymphoma, Mantle-Cell (4) · Myelodysplastic Syndromes (4) · Neoplasms (4) · Disease Progression (3)
Sponsors
Celgene (21) · Janssen Research & Development, LLC (9) · National Cancer Institute (NCI) (8) · Celgene Corporation (7) · The Lymphoma Academic Research Organisation (6) · Fondazione EMN Italy Onlus (5) · PETHEMA Foundation (5) · Bristol-Myers Squibb (4) · Incyte Corporation (4) · Ruijin Hospital (4) · University of Heidelberg Medical Center (4) · ECOG-ACRIN Cancer Research Group (3) · Genmab (3) · Kite, A Gilead Company (3) · SWOG Cancer Research Network (3)
Countries
United States (81) · France (68) · Germany (64) · Spain (64) · Italy (57) · United Kingdom (55) · Belgium (50) · Australia (49) · Canada (47) · Poland (45) · China (40) · Czechia (40) · Israel (37) · Austria (34) · Greece (34)
Top investigators
Robert Knight, MD (5) · Francesca Gay, MD (2) · Franck Morschhauser, MD, PhD (2) · Hartmut Goldschmidt, Prof. Dr. (2) · Hermann Einsele, MD (2)
Results publications
PMID 31221778, PMID 35985959, PMID 18799726, PMID 19901114, PMID 21273172, PMID 23194056, PMID 30561775, PMID 34289038, PMID 34587246, PMID 37990162, PMID 38023148, PMID 38031761, PMID 38048552, PMID 38062124, PMID 39229471, PMID 39293025, PMID 39374535, PMID 41915772, PMID 18032762, PMID 18032763, PMID 18757334, PMID 19332768, PMID 19853510, PMID 20876454, PMID 21109690, PMID 21495023, PMID 21753188, PMID 21835953, PMID 21860025, PMID 22292853, PMID 22571200, PMID 22571201, PMID 22571202, PMID 22689675, PMID 23242595, PMID 23422747, PMID 23834234, PMID 24682512, PMID 25184862, PMID 25481539, PMID 25482145, PMID 25616460, PMID 25628469, PMID 25629741, PMID 25743937, PMID 25760767, PMID 25798669, PMID 25840600, PMID 26035255, PMID 26157076
NIH funding
2023 (14), U10CA180820 (9), 2009 (6), U10CA021115 (6), 2025 (5), 2018 (3), U10CA180888 (3), U24CA196172 (3), 2005 (2), 2015 (2), 2017 (2), 2019 (2), U01HL069294 (2), U10CA032102 (2), U10CA180821 (2)